RAANANA, Israel, May 11, 2015 /PRNewswire/ --
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL)
("XTL" or the "Company"), a clinical-stage biopharmaceutical
company focused on the acquisition, development and
commercialization of pharmaceutical products for the treatment of
unmet clinical needs, announced today that the company will present
at the IATI Biomed 2015 Conference on May
12, 2015:
Date: May 12, 2015
Presenter: Josh Levine, Chief Executive Officer
Time: 6:00 pm Israel Time
Location: Hall C6, Tel Aviv Convention Center, Israel
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd., a biopharmaceutical company,
focuses on the acquisition, development, and commercialization of
pharmaceutical products for the treatment of unmet clinical needs.
XTL is focused on late stage clinical development of drugs for the
treatment of lupus and multiple myeloma.
XTL is a public company traded on the Nasdaq Capital Market
(NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL
shares are included in the following indices: Tel-Aviv Biomed,
Tel-Aviv MidCap, and Tel-Aviv Tech Index.
For more information, the content of which is not part of this
press release, please visit http://www.xtlbio.com
Cautionary Statement
Some of the statements included in this press release may be
forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. Please see the risk
factors associated with an investment in our ADSs or ordinary
shares which are included in our Annual Report on Form 20-F as
filed with the U.S. Securities and Exchange Commission on
April 28, 2015.
Investor Contacts:
Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972-9-955-7080
Email: ir@xtlbio.com
http://www.xtlbio.com
SOURCE XTL Biopharmaceuticals Ltd